RESUMEN
Introduction: Endometriosis is a chronic disease characterizedby the proliferation of endometrial tissue outside the uterinecavity, and it occurs in 6% to 10% of women of reproductiveage and in 50% of infertile women. Current research aimed tostudy the safety and efficacy of dinogest 2mg daily in patientsof endometriosis for a period of 12 months.Material and methods: This study was a retrospective nonplacebo randomized trial done in the department of obstetricsand gynaecology, RMCH. Patient data was collected in a spanof 1year i.e; February 2018 to January 2019 and dinogestwas given for 12 months thereafter. Total 100 women postsurgery (cystectomy) with endometriosis were taken who hadbeen treated with 2mg of dinogest once a day for 12 months.We evaluated changes in endometriosis associated pain,endometrioma size, recurrence rate and adverse events.Result: Pain was significantly reduced at 12 monthsafter dinogest medication. The size of endometrioma wassignificantly decreased at the 12th month. Only 1 case ofsonographic recurrence was seen. The most common adversedrug reaction was uterine bleeding (1%) with minor sideeffects which became gradually tolerable.Conclusion: Administration of dinogest for a one yearperiod seems to be highly effective in preventing recurrenceafter surgery, there was marked reduction in endometriosisassociated pain and decreasing the size of recurrentendometrioma. So, it is very safe and tolerable drug fortreatment of endometriosis.